Retatrutide
TRIUMPH-1
Eli Lilly · Phase 3 · Completed · Enrollment 2335
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| retatrutide 4 mg | Obesity, no T2D | 4 mg | 80 | ITT | -17.6% at week 80 |
| retatrutide 9 mg | Obesity, no T2D | 9 mg | 80 | ITT | -23.7% at week 80 |
| retatrutide 12 mg | Obesity, no T2D | 12 mg | 80 | ITT | -25% at week 80 |
| Placebo | Obesity, no T2D | n/r | 80 | ITT | -3.9% at week 80 |